Mouse Models of Novel Sphingolipid Biology and Disease Mechanisms

$742,052ZIAFY2019DKNIH

National Institute Of Diabetes And Digestive And Kidney Diseases

Investigators

Linked publications & trials

Paper 39647513 Paper 37871851 Paper 37071464 Paper 36753412 Paper 36709532 Paper 35917044 Paper 34297830 Paper 33926208 Paper 33301355 Paper 33296739 Paper 32722120 Paper 32179479 Paper 32091396 Paper 32029474 Paper 31171507 Paper 31147448 Paper 31123291 Paper 30997640 Paper 30060257 Paper 29693558 Paper 29383825 Paper 29079828 Paper 28100772 Paper 27872583 Paper 27226645 Paper 27059959 Paper 26268607 Paper 26053123 Paper 25954148 Paper 25831442 Paper 25829545 Paper 25498971 Paper 25395622 Paper 25351657 Paper 25332431 Paper 25253697 Paper 25250575 Paper 24667638 Paper 24659784 Paper 24090699 Paper 24081141 Paper 23904439 Paper 23637227 Paper 23392686 Paper 23359503 Paper 23148237 Paper 22735358 Paper 22606352 Paper 22504650 Paper 21642988 Paper 21248243 Paper 21173151 Paper 20950672 Paper 20407207 Paper 20404103 Paper 20097939 Paper 19705459 Paper 19483717 Paper 19251691 Paper 19204730 Paper 19109558 Paper 18424450 Paper 18199826

Abstract

The sphingolipid metabolic pathway yields highly active lipid signaling molecules that regulate many physiologic processes during development and for homeostasis in the adult. Furthermore, the pathway is highly regulated and appears to function abnormally in certain disordered states such as in cancer and in metabolic diseases. We are utilizing genetically altered mice that are modified in their sphingolipid metabolism and signaling to uncover new functions of sphingolipids in normal biology and in disease.

View original record on NIH RePORTER →